Congress Orders DEA Crackdown on Intoxicating Cannabinoids While CMS Continues Expanding Medicare CBD Access - newswire.com
Congress mandates DEA crackdown on intoxicating cannabinoids while CMS expands Medicare CBD access.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 9, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers involved in cannabinoid products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate review and adjustment as regulations are enforced.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Increased regulatory scrutiny on intoxicating cannabinoids by the DEA, while Medicare access for CBD is being expanded.
Who it affects
All pharmaceutical manufacturers involved in cannabinoid products.
What you must do
Review product lines for compliance with new DEA regulations and prepare for potential changes in market access due to Medicare expansions.
Deadline
Immediate review and adjustment as regulations are enforced.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Senate Unanimously Passes Boscola-Backed Legislation to Modernize Pharmaceutical Licensing - pasenate.com
- USFDA flags 3 manufacturing compliance lapses at Lupin's New Jersey unit - Business Standard
- Comments on DEA’s proposed rule on manufacturing and procurement quotas - brookings.edu
- Arkansas passes law banning PBMs from owning pharmacies - Healthcare Dive
- State Marijuana Products Can Not Enter Schedule III Without Demonstrating the Chemical Consistency Required by Federal Regulation - newswire.com